Researchers from Taiwan followed dozens of children who screened positive for deafness-related genotypes at birth, identifying those with hearing loss over six years.
By testing hundreds of children with brain tumors who were treated with cisplatin, researchers identified risk variants related to cisplatin ototoxicity.
In preparation for the launch, the laboratory is currently exploring the test in a clinical research setting and is hoping to sequence its first genome next month.
University of Iowa and Baylor College of Medicine researchers reported that they have developed and tested a method that uses target enrichment and massively parallel sequencing to find variants behind non-syndromic hearing loss.
